David Schiff

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint Central nervous system toxicity from cancer therapies
    David Schiff
    Neuro Oncology Center, University of Virginia, Box 800432, Charlottesville, VA 22908 0432, USA
    Hematol Oncol Clin North Am 20:1377-98. 2006
  2. ncbi request reprint Epidural Spinal Cord Compression
    Robert Cavaliere
    Division of Neuro Oncology, Department of Neurology, University of Virginia, Box 800432, Charlottesville, VA 22908, USA
    Curr Treat Options Neurol 6:285-295. 2004
  3. doi request reprint Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
    David Schiff
    University of Virginia Neuro Oncology Center, Box 800432, Charlottesville, VA, 22908 0432, USA
    Invest New Drugs 33:247-53. 2015
  4. ncbi request reprint Outcome in adult low-grade glioma: the impact of prognostic factors and treatment
    David Schiff
    Neuro Oncology Center, University of Virginia Health Sciences Center, Box 800432, Charlottesville, VA 22908 0432, USA
    Neurology 69:1366-73. 2007
  5. ncbi request reprint Neuropathological correlates of reversible posterior leukoencephalopathy
    David Schiff
    Division of Neuro Oncology, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Neurocrit Care 2:303-5. 2005
  6. ncbi request reprint Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma
    David Schiff
    Department of Neurological Surgery, University of Pittsburgh Medical Center, USA
    J Neurooncol 65:173-5. 2003
  7. ncbi request reprint Role of resection for newly diagnosed malignant gliomas
    David Schiff
    Department of Neurology, University of Virginia Health Science Center, Charlottesville 22908, USA
    Expert Rev Anticancer Ther 3:621-30. 2003
  8. ncbi request reprint Gliomas following organ transplantation: analysis of the contents of a tumor registry
    David Schiff
    Division of Neuro Oncology, University of Virginia Health System, Charlottesville, Virginia 22909 0432, USA
    J Neurosurg 101:932-4. 2004
  9. ncbi request reprint Spinal cord compression
    David Schiff
    Neuro Oncology Center, University of Virginia Medical Center, Box 800432, Charlottesville, VA 22908 0432, USA
    Neurol Clin 21:67-86, viii. 2003
  10. pmc Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy
    Fadila Guessous
    Department of Microbiology, University of Virginia, Charlottesville, VA 22908, USA
    Mol Cancer Ther 11:288-97. 2012

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint Central nervous system toxicity from cancer therapies
    David Schiff
    Neuro Oncology Center, University of Virginia, Box 800432, Charlottesville, VA 22908 0432, USA
    Hematol Oncol Clin North Am 20:1377-98. 2006
    ..Novel methods of delivering radiation and chemotherapy agents have led to recognition of new forms of CNS neurotoxicity. In this article, the authors review the most important CNS toxicities of cancer treatment...
  2. ncbi request reprint Epidural Spinal Cord Compression
    Robert Cavaliere
    Division of Neuro Oncology, Department of Neurology, University of Virginia, Box 800432, Charlottesville, VA 22908, USA
    Curr Treat Options Neurol 6:285-295. 2004
    ..This is particularly true in radio-responsive tumors, such as myeloma and lymphoma, in which surgery may be avoided entirely. Chemotherapy may play a role as adjuvant therapy in some tumors...
  3. doi request reprint Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
    David Schiff
    University of Virginia Neuro Oncology Center, Box 800432, Charlottesville, VA, 22908 0432, USA
    Invest New Drugs 33:247-53. 2015
    ..Despite biological activity and a tolerable side effect profile, CT-322 failed to meet the prespecified threshold for efficacy in recurrent glioblastoma...
  4. ncbi request reprint Outcome in adult low-grade glioma: the impact of prognostic factors and treatment
    David Schiff
    Neuro Oncology Center, University of Virginia Health Sciences Center, Box 800432, Charlottesville, VA 22908 0432, USA
    Neurology 69:1366-73. 2007
    ..We review contemporary knowledge regarding prognostic factors, our current evidence-based understanding of the roles and timing of radiation and chemotherapy, and ongoing clinical trials that will further elucidate management of LGGs...
  5. ncbi request reprint Neuropathological correlates of reversible posterior leukoencephalopathy
    David Schiff
    Division of Neuro Oncology, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Neurocrit Care 2:303-5. 2005
    ..This supports the concept that the imaging changes on MRI represent vasogenic edema and suggests that the changes observed on autopsy in malignant hypertension may be an epiphenomenon...
  6. ncbi request reprint Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma
    David Schiff
    Department of Neurological Surgery, University of Pittsburgh Medical Center, USA
    J Neurooncol 65:173-5. 2003
    ..We report the first case of stiff-limb syndrome in a patient with multiple myeloma undergoing treatment with thalidomide, and explore the potential link to the cancer and its treatment...
  7. ncbi request reprint Role of resection for newly diagnosed malignant gliomas
    David Schiff
    Department of Neurology, University of Virginia Health Science Center, Charlottesville 22908, USA
    Expert Rev Anticancer Ther 3:621-30. 2003
    ..The absence of randomized clinical trials and paucity of prospectively collected information continue to leave this issue unresolved, although most evidence continues to support a modest benefit of debulking over biopsy...
  8. ncbi request reprint Gliomas following organ transplantation: analysis of the contents of a tumor registry
    David Schiff
    Division of Neuro Oncology, University of Virginia Health System, Charlottesville, Virginia 22909 0432, USA
    J Neurosurg 101:932-4. 2004
    ..The author sought to examine the association between the immunosuppressive state in organ transplant recipients and the development of gliomas...
  9. ncbi request reprint Spinal cord compression
    David Schiff
    Neuro Oncology Center, University of Virginia Medical Center, Box 800432, Charlottesville, VA 22908 0432, USA
    Neurol Clin 21:67-86, viii. 2003
    ..This article reviews the clinical features, differential diagnosis, and management of neoplastic epidural spinal cord compression...
  10. pmc Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy
    Fadila Guessous
    Department of Microbiology, University of Virginia, Charlottesville, VA 22908, USA
    Mol Cancer Ther 11:288-97. 2012
    ....
  11. pmc MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
    Yunqing Li
    Departments of Microbiology, Neurology and Pathology, University of Virginia, Charlottesville, VA 22908, USA
    Cancer Res 69:7569-76. 2009
    ..They show that miR-34a suppresses brain tumor growth by targeting c-Met and Notch. The results also suggest that miR-34a could serve as a potential therapeutic agent for brain tumors...
  12. pmc Oncogenic effects of miR-10b in glioblastoma stem cells
    Fadila Guessous
    Departments of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA
    J Neurooncol 112:153-63. 2013
    ..Targeting miR-10b might therefore inhibit glioblastoma stem cells, which are thought to be at the origin of glioblastoma and to contribute its recurrence and resistance to therapy...
  13. ncbi request reprint Medical management of brain tumor patients
    Jan Drappatz
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Neurol Clin 25:1035-71, ix. 2007
    ..Effective medical management results in decreased morbidity and mortality and improved quality of life for affected patients...
  14. pmc Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition
    Ying Zhang
    Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 19:1433-44. 2013
    ..The purpose of this study was to investigate the not-well-known molecular determinants that predict responsiveness to c-MET inhibitors and to explore new strategies for improving inhibitor efficacy in brain tumors...
  15. pmc A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy
    Xiaoping Huang
    Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA
    Neoplasia 15:952-65. 2013
    ..The data also indicate that the combined mutational status of PTEN and p53 influences cancer prognosis and anticancer therapies that target PTEN and p53...
  16. ncbi request reprint The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas
    Mark E Shaffrey
    Department of Neurosurgery, University of Virginia, Charlottesville, Virginia, USA
    J Neurosurg 102:1033-9. 2005
    ..This study was conducted to determine whether proliferative tumor activity, as assessed using the Ki-67 immunohistochemical labeling index (LI), has prognostic utility for patients with Grade II oligoastrocytomas...
  17. pmc microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
    Fadila Guessous
    Department of Microbiology, University of Virginia, Charlottesville, VA, USA
    Cell Cycle 9:1031-6. 2010
    ..Altogether, the data suggest that miR-34a is a tumor suppressor and a potential potent therapeutic agent that acts by targeting multiple oncogenic pathways in brain tumors and by inducing the differentiation of cancer stem cells...
  18. pmc microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma
    JungEun Kim
    Authors Affiliations Departments of Microbiology, Immunology and Cancer Biology, Neurology, and Cancer Center, University of Virginia, Charlottesville, Virginia Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom and Department of Neurosurgery, Brigham and Women s Hospital, Boston, Massachusetts
    Cancer Res 74:1541-53. 2014
    ..Taken together, our findings provide a comprehensive analysis of the prognostic value and oncogenic function of miR-148a in glioblastoma, further defining it as a potential target for glioblastoma therapy...
  19. doi request reprint Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas
    Jonathan H Sherman
    Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia, USA
    J Neurosurg 114:1617-21. 2011
    ..The oral alkylating agent temozolomide has emerged as a potential initial treatment option for LGG. A few reports suggest an association between temozolomide and reduced seizure frequency in patients with intractable epilepsy...
  20. pmc An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth
    Fadila Guessous
    Departments of Microbiology, University of Virginia, Charlottesville, USA
    Anticancer Agents Med Chem 10:28-35. 2010
    ..These findings suggest that targeting c-Met with small molecule kinase inhibitors is a promising approach for brain tumor therapy...
  21. ncbi request reprint Medical management of patients with brain tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
    J Neurooncol 80:313-32. 2006
    ..Medications such as modafinil and methylphenidate have assumed an increasing role in the treatment of fatigue, while donepezil and memantine may be helpful with memory loss...
  22. doi request reprint MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status
    Jonathan H Sherman
    Department of Neurological Surgery, University of Virginia, P O Box 800212, Health Sciences Center, Charlottesville, VA 22908, USA
    Acta Neurochir (Wien) 152:1827-34. 2010
    ..MR imaging can be used to help differentiate between low- and high-grade tumors. We hypothesize that certain MR imaging characteristics can be used to differentiate between patients with and without 1p and 19q deletion...
  23. ncbi request reprint Brain metastases
    Mark E Shaffrey
    Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA
    Curr Probl Surg 41:665-741. 2004
  24. pmc XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC
    Ying Zhang
    University of Virginia, Department of Microbiology, PO Box 800168, Charlottesville, Virginia, 22903, USA
    IDrugs 13:112-21. 2010
    ....
  25. doi request reprint Neurological adverse effects caused by cytotoxic and targeted therapies
    David Schiff
    Department of Neurology, University of Virginia in Charlottesville, VA 22908 0432, USA
    Nat Rev Clin Oncol 6:596-603. 2009
    ..These agents include DNA-damaging agents such as oxaliplatin and temozolomide, microtubule poisons like ixabepilone, proteasome inhibitors (bortezomib), and signal transduction inhibitors such as imatinib, sunitinib and bevacizumab...
  26. pmc MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET
    Ying Zhang
    Departments of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia, United States of America
    PLoS ONE 9:e91546. 2014
    ..These findings demonstrate for the first time that miR-608 and miR-34a regulate chordoma malignancy by regulating EGFR, MET and Bcl-xL. ..
  27. doi request reprint Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
    Patrick G Morris
    Patrick G Morris, Denise D Correa, Joachim Yahalom, Anne S Reiner, Kathy Panageas, Sasan Karimi, Richard Curry, Gaurav Shah, Lauren E Abrey, Lisa M DeAngelis, and Antonio Omuro, Memorial Sloan Kettering Cancer Center Rose K Lai, Columbia University, New York, NY Jeffrey J Raizer and Sean Grimm, Northwestern University, Chicago, IL David Schiff, University of Virginia, Charlottesville, VA and Barbara Grant, University of Vermont, Burlington, VT
    J Clin Oncol 31:3971-9. 2013
    ....
  28. doi request reprint Low-grade gliomas in older patients: a retrospective analysis of prognostic factors
    Nader Pouratian
    Department of Neurological Surgery, University of Virginia, Box 800212, Charlottesville, VA 22908 0212, USA
    J Neurooncol 90:341-50. 2008
    ..Similarities with previous reports of LGG suggest that age should not affect the management of LGG patients. Prospective studies of older patients with LGG are needed to further characterize the optimum management of these patients...
  29. ncbi request reprint Bone health in patients with brain tumors
    Arnaldo Neves Da Silva
    Neurology Department, University of Virginia, Charlottesville, VA 22908, USA
    Surg Neurol 68:525-33; discussion 533. 2007
    ..Several factors, including the use of antiepileptic drugs, glucocorticoids, anticoagulants, chemotherapy, radiation therapy, and hemiplegia-associated osteopenia, render patients with brain tumor susceptible to bone disease...
  30. ncbi request reprint Clinical implications of status epilepticus in patients with neoplasms
    Robert Cavaliere
    Department of Neurology, Ohio State University, Columbus, OH, USA
    Arch Neurol 63:1746-9. 2006
    ..To elucidate factors that contribute to the development of status epilepticus (SE) and determine prognostic factors and the impact on 30-day survival...
  31. ncbi request reprint Surgery Insight: the role of surgery in the management of low-grade gliomas
    Nader Pouratian
    University of Virginia, Charlottesville, VA, USA
    Nat Clin Pract Neurol 3:628-39. 2007
    ..As a result of advances in surgical techniques, the time might now be right to effectively and accurately assess the influence of aggressive surgical resection on the prognosis of low-grade gliomas...
  32. doi request reprint Angiogenic inhibition in high-grade gliomas: past, present and future
    Jasmin Jo
    Department of Neurology, Division of Neuro Oncology, University of Virginia, Charlottesville, VA 22908 0432, USA
    Expert Rev Neurother 12:733-47. 2012
    ..Identification of neuroimaging advances and biologic markers will greatly enhance treatment strategies for these patients...
  33. doi request reprint Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression
    Zachary M Bush
    Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia 22908 0214, USA
    J Clin Endocrinol Metab 95:E280-90. 2010
    ..Recently, case reports have described efficacy of temozolomide for the treatment of aggressive pituitary tumors...
  34. ncbi request reprint Novel therapies for malignant gliomas
    Robert Cavaliere
    Division of Neuro Oncology, Ohio State University, 463 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Neurol Clin 25:1141-71, x. 2007
    ..Yet much research is still needed at all levels, from the identification of molecular markers to the development and application of novel therapeutics...
  35. pmc Glioblastoma genetics: in rapid flux
    Benjamin W Purow
    Neuro Oncology Center, Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, USA
    Discov Med 9:125-31. 2010
    ..The likely impact on care delivery in the clinic may only be a few years away. The rapid and exciting pace of advances in glioblastoma genetics has prompted this up-to-date review...
  36. ncbi request reprint Neuromuscular complications of cancer diagnosis and treatment
    Mohamed Falah
    Department of Neurology, University of Virginia, Charlottesville 22908, USA
    J Support Oncol 3:271-82. 2005
    ..Early recognition and management of these disorders will improve patient outcome and quality of life...
  37. pmc Medical management of brain tumors and the sequelae of treatment
    David Schiff
    Neuro Oncology Center, University of Virginia Medical Center, Charlottesville, Virginia D S Center for Neuro Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts E Q L, L N, A D N, D A R, P Y W
    Neuro Oncol 17:488-504. 2015
    ....
  38. doi request reprint Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma
    Jasmin Jo
    Division of Neuro Oncology, Department of Neurology, University of Virginia, Hospital West Room 6225, PO Box 800432, Charlottesville, VA, 22908, USA
    J Neurooncol 120:155-61. 2014
    ..Although this tumor shrinkage might facilitate radical surgical resection in some cases, our data failed to show statistically significant improvement in anticipated EOR...
  39. doi request reprint Multimodal MR imaging model to predict tumor infiltration in patients with gliomas
    Christopher R Durst
    University of Virginia Health Systems, Division of Neuroradiology, Department of Radiology and Medical Imaging, PO Box 800170, Fedex 1215 Lee Street New Hospital, Charlottesville, VA, 22908, USA
    Neuroradiology 56:107-15. 2014
    ..The goal of our study was to evaluate if a combination of advanced MR imaging techniques and a multimodal imaging model could be used to predict tumor infiltration in patients with diffuse gliomas...
  40. pmc The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses
    Alexander V Kofman
    Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA
    Med Hypotheses 81:62-7. 2013
    ..We hypothesize that p53-microRNA-34a axis may alter susceptibility of cells to infection with some viruses that are detected in tumors and either proven or suspected to be associated with tumor initiation and progression...
  41. doi request reprint A model for the regulation of T-type Ca(2+) channels in proliferation: roles in stem cells and cancer
    Lloyd S Gray
    Tau Therapeutics, LLC, 600 E Water Street, Charlottesville, VA 22902, USA
    Expert Rev Anticancer Ther 13:589-95. 2013
    ..The model illustrates the essential role of T-type Ca(2+) channels in mediating influx and points clearly to the therapeutic strategies that have recently entered clinical trials...
  42. doi request reprint Subependymal seeding of low-grade oligodendroglial neoplasms: a case series
    Manal Nicolasjilwan
    Department of Radiology, Neuroradiology Division, University of Virginia, Charlottesville, VA 22908 0170, USA
    J Neurooncol 108:99-108. 2012
    ..All six patients were males...
  43. ncbi request reprint Rare pathological variants and presentations of primary central nervous system lymphomas
    Arnaldo Neves Da Silva
    Neurology Department, Division of Neuro Oncology, University of Virginia Health Sciences Center, Jefferson Park Avenue, Hospital West, Room 6228, PO Box 800432, Charlottesville, Virginia 22908 0432, USA
    Neurosurg Focus 21:E7. 2006
    ..The authors describe unusual pathological forms of PCNSLs, including low-grade, T-cell, and Burkitt types, and also rare presentations such as neurolymphomatosis and pituitary lymphomas...
  44. ncbi request reprint Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation
    David Schiff
    Neuro Oncology Center, University of Virginia, Charlottesville, Virginia, USA
    Cancer Invest 25:776-84. 2007
    ..Additionally, they will measure cognition and quality of life to determine if improvements in time to progression translate into better functional status and patient satisfaction...
  45. ncbi request reprint Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas
    Nader Pouratian
    Department of Neurological Surgery, University of Virginia, Box 800212, Charlottesville, VA 22908 0212, USA
    J Neurooncol 82:281-8. 2007
    ..The results of larger randomized trials are needed to assess its potential advantages over other management schemes...
  46. ncbi request reprint Pituitary carcinoma: diagnosis and treatment
    M Beatriz S Lopes
    Department of Pathology Neuropathology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    Endocrine 28:115-21. 2005
    ..This article reviews the clinical presentation of these tumors, their neuroimaging and pathological features, tumor pathogenesis, and possible treatment modalities...
  47. doi request reprint Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia
    Dawit G Aregawi
    Department of Neurology, University of Virginia, Charlottesville, Virginia, USA
    Muscle Nerve 38:1196-200. 2008
    ..In selected patients presenting with peripheral neuropathy, MRI and PET scan can be helpful in the diagnosis of peripheral nerve infiltration...
  48. ncbi request reprint Part II: spinal-cord neoplasms--primary tumours of the bony spine and adjacent soft tissues
    Charles A Sansur
    Department of Neurosurgery, University of Virginia Health System, Charlottesville, VA 22908, USA
    Lancet Oncol 8:137-47. 2007
    ....
  49. ncbi request reprint Neurologic toxicities of cancer therapies
    Robert Cavaliere
    Ohio State University, Department of Neurology, Room 463 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Curr Neurol Neurosci Rep 6:218-26. 2006
    ..In particular, oxaliplatin, thalidomide, methotrexate, ifosfamide, cytarabine, amifostine, acetyl-L-carnitine, methylene blue, cytokines, and neurotrophins are discussed...
  50. ncbi request reprint Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua
    Melike Mut
    Department of Neurosurgery, University of Virginia, CDW Hospital Drive, P O Box 800212, Charlottesville, VA 22903, USA
    J Neurooncol 72:63-6. 2005
    ..The diagnostic challenges of the highly variable clinical presentations and therapeutic approaches to paraneoplastic multifocal encephalitis are discussed with relevant literature review...
  51. ncbi request reprint Intraventricular gliomas
    Aaron S Dumont
    Department of Neurological Surgery, University of Virginia Health Sciences Center, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA
    Neurosurg Clin N Am 14:571-91. 2003
    ..Future cooperative intra- and interinstitutional efforts between scientists and clinicians will hopefully culminate in an improved outlook and eventual cure for patients with gliomas...
  52. ncbi request reprint Cintredekin besudotox in treatment of malignant glioma
    Melike Mut
    Hacettepe Hastanesi Beyin Cerrahisi, Bolum 71 Sihhiye, Ankara 06100, Turkey
    Expert Opin Biol Ther 8:805-12. 2008
    ..Interleukin-13 (IL-13) receptors are overexpressed in glioblastoma multiforme (GBM). The presence of IL-13 binding sites in GBM and their absence in normal brain tissue validates IL-13 receptor as an important target in human GBM...
  53. pmc Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells
    Pítia F Ledur
    Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia P F L, C L, A R H, H Z Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia M E S, A A, D S Division of Neuropathology, Department of Pathology, Charlottesville, Virginia M B S L, J W M Department of Neurology, School of Medicine, University of Virginia, Charlottesville, Virginia D S Department of Pathology and Pathological Physiology, Center for Cancer Research, Zhejiang University School of Medicine, Zhejiang Diseases Proteomics Key Laboratory, Hangzhou, China C L Department of Biophysics and Center of Biotechnology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil P F L, D C M, G L Department of Neurosurgery, Changzheng Hospital, Second Affiliated Hospital of Second Military Medical University, Shanghai, China H H, Y C L Department of Pathology, Xiang Ya Hospital, Central South University, Changsha, Hunan, Department of Biology
    Neuro Oncol 18:1413-24. 2016
    ....
  54. ncbi request reprint Low-grade gliomas: an update on pathology and therapy
    Robert Cavaliere
    Neuro Oncology Center, University of Virginia, Box 800432, Charlottesville, VA 22908, USA
    Lancet Neurol 4:760-70. 2005
    ..Ongoing clinical trials will help to elucidate the optimum management of patients with LGG...
  55. pmc The roles of viruses in brain tumor initiation and oncomodulation
    Alexander Kofman
    Department of Microbiology, University of Virginia, P O Box 800168, Charlottesville, VA 22908, USA
    J Neurooncol 105:451-66. 2011
    ....
  56. ncbi request reprint Metastasis to nervous system: spinal epidural and intramedullary metastases
    Melike Mut
    Department of Neurosurgery, University of Virginia, Charlottesville 22908 0432, USA
    J Neurooncol 75:43-56. 2005
    ..Intramedullary metastasis is rare but should be considered in patients with systemic malignancy and asymmetrical presentation of myelopathic symptoms. The prognosis is usually poor and preferred modality of treatment is radiotherapy...
  57. ncbi request reprint Metastatic spinal cord compression by solid tumors
    Kristin Gabriel
    Virginia Commonwealth University Medical Center, Department of Neurology, Richmond, Virginia, USA
    Semin Neurol 24:375-83. 2004
    ..These treatment options will be considered according to patients' disease burden, life expectancy, and values. Intramedullary metastasis will be briefly discussed...
  58. ncbi request reprint Neurologic complications of chemotherapy agents
    George Kannarkat
    Division of Hematology Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia 22908 0432, USA
    Curr Opin Neurol 20:719-25. 2007
    ..To review neurologic complications of common and recently developed chemotherapeutic agents, as well as recent research regarding 'chemobrain'...
  59. pmc Advances in the genetics of glioblastoma: are we reaching critical mass?
    Benjamin Purow
    Neuro Oncology Division, Neurology Department, University of Virginia, Charlottesville, VA 22908, USA
    Nat Rev Neurol 5:419-26. 2009
    ..In addition, the complex task of incorporating our updated knowledge into new--and possibly personalized--therapies for patients with glioblastoma still lies ahead...
  60. ncbi request reprint Malignant spinal-cord compression
    Dheerendra Prasad
    Department of Radiation Oncology, University of Virginia, Charlottesville, VA, USA
    Lancet Oncol 6:15-24. 2005
    ..We also emphasise advances in radiation delivery and the results of a randomised trial that supported aggressive debulking in patients with MSCC...
  61. ncbi request reprint Supportive management of patients with brain tumors
    Farrah N Daly
    University of Virginia Health System, Neuro Oncology Center, Box 800432, Charlottesville, VA 22908 0432, USA
    Expert Rev Neurother 7:1327-36. 2007
    ..Above all, patients' personal goals regarding their priorities at the end of life have the most importance...
  62. ncbi request reprint Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor
    Arnaldo Neves Da Silva
    Division of Neuro Oncology, Department of Neurology, University of Virginia Health System, PO Box 800432, Charlottesville, VA 22908 0432, USA
    Surg Neurol 67:508-10. 2007
    ..Rapid GC tapering may not only decompensate intracranial pressure, but also unmask SAI, and some symptoms of SAI can be mistakenly attributable to increased intracranial pressure or side effects of chemotherapy and radiation therapy...
  63. pmc Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  64. doi request reprint Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas
    Andrew D Norden
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA, 02115, USA
    J Neurooncol 121:297-302. 2015
    ..6 months (1.0-6.9). Among AG patients in each arm, PFS6 was 0 %. Treatment was well tolerated. In conclusion, nintedanib is not active against recurrent high-grade glioma, regardless of prior bevacizumab therapy...
  65. doi request reprint Disseminated strongyloidiasis complicating glioblastoma therapy: a case report
    Dawit Aregawi
    Neuro Oncology Center and Departments of Neurology, Neurological Surgery, and Medicine Hematology Oncology, University of Virginia, Charlottesville, VA 22908 0432, USA
    J Neurooncol 94:439-43. 2009
    ..Strongyloidiasis should be considered in patients being treated for glioma who have lived or traveled to high risk areas and developed gram negative sepsis, along with gastrointestinal or respiratory symptoms, skin rash or SIADH...
  66. doi request reprint Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas
    David Schiff
    University of Virginia Neuro Oncology Center, Charlottesville, VA 22908 0432, USA
    Nat Rev Neurol 5:303-4. 2009
    ..These mutations are essentially unique to gliomas, seem to represent an early step in gliomagenesis, and confer a favorable prognosis...
  67. ncbi request reprint Neurologic complications of solid tumors
    Patrick Y Wen
    Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St Boston, MA 02115, USA
    Neurol Clin 21:107-40, viii. 2003
    ..As systemic therapy improves for many of these tumors, patients are surviving longer and the incidence of neurologic complications is increasing...
  68. ncbi request reprint Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008
    ..Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients...
  69. doi request reprint Metastatic epidural spinal cord compression
    Jennie W Taylor
    Department of Neurology, University of Virginia Health System, Charlottesville, Virginia 22908 0432, USA
    Semin Neurol 30:245-53. 2010
    ..Special attention will be given to the supportive and definitive treatments available for management, and new therapeutic interventions, such as radiosurgery, will be briefly discussed as well...
  70. ncbi request reprint Part I: spinal-cord neoplasms-intradural neoplasms
    David E Traul
    Department of Neurology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Lancet Oncol 8:35-45. 2007
    ..In this Review, we discuss the published work on intradural spinal-cord tumours in terms of epidemiological, radiographic, and histological characteristics. Surgical and adjuvant treatment strategies are also reviewed...
  71. doi request reprint Update on molecular findings, management and outcome in low-grade gliomas
    T David Bourne
    University of Virginia Health System, Department of Pathology, Division of Neuropathology, Charlottesville, VA 22908 0214, USA
    Nat Rev Neurol 6:695-701. 2010
    ..Ultimately, molecular marker assessment will, hopefully, improve the accuracy of tumor diagnosis and enhance the effectiveness of treatment to achieve improved patient outcomes...
  72. ncbi request reprint Fatal pulmonary embolism despite an inferior vena cava filter in glioblastoma multiforme
    Robert Cavaliere
    Department of Neurology, Ohio State University, Columbus, OH, USA
    Neurocrit Care 3:249-50. 2005
    ..Patients with high-grade gliomas are at increased risk of pulmonary embolism and deep vein thrombosis. Treatment of this complication remains uncertain and options include anticoagulation or venous filters...
  73. pmc PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
    Yunqing Li
    Department of Neurology, University of Virginia, Charlottesville, Virginia 22908, USA
    Cancer Res 68:1723-31. 2008
    ..The findings also provide an explanation for the low frequency of simultaneous mutations of PTEN and p53 in human cancer...
  74. ncbi request reprint Dural and skull base metastases
    Arnaldo Neves Da Silva
    University of Virginia, Neurology Department, Division of Neuro Oncology, Charlottesville, VA 22908 0432, USA
    Cancer Treat Res 136:117-41. 2007
  75. doi request reprint Dephosphorylation of beta-arrestin 1 in glioblastomas
    James W Mandell
    Department of Pathology, University of Virginia Health System, Charlottesville, VA 22903, USA
    J Neuropathol Exp Neurol 68:535-41. 2009
    ..These results suggest that beta-arrestin 1 dephosphorylation/inactivation is associated with aspects of the malignant behavior of glioblastomas...
  76. doi request reprint Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
    Yunqing Li
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Mol Cancer Ther 8:376-85. 2009
    ....
  77. ncbi request reprint Reversible posterior leukoencephalopathy syndrome in cancer
    Christopher Vaughn
    Division of Hematology Oncology, University of Virginia Health System, PO Box 800716, Charlottesville, VA 22908, USA
    Curr Oncol Rep 10:86-91. 2008
    ..An increased number of case reports involving new targeted agents suggests that RPLS incidence may increase in the future. Agents such as bevacizumab and sorafenib have been implicated in new cases of RPLS...
  78. ncbi request reprint Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients
    Dhruv Singhal
    Department of Neurological Surgery, University of Pittsburgh, Pennsylvania 15213, USA
    Can J Neurol Sci 29:147-53. 2002
    ..We reviewed survival data for our series of patients treated for PCL over the last decade...
  79. ncbi request reprint Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma
    Yunqing Li
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Lab Invest 88:98-111. 2008
    ..The findings provide a potential explanation for the high frequency of c-Myc overexpression in medulloblastoma and suggest a cooperative role for c-Met and c-Myc in large-cell anaplastic medulloblastoma formation...
  80. ncbi request reprint Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
    Kurt A Jaeckle
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 21:2305-11. 2003
    ..This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG...
  81. pmc Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
    Neuro Oncol 10:300-8. 2008
    ..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment...
  82. ncbi request reprint Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    Henry E Singleton Brain Cancer Research Program, University of California, Los Angeles, CA, USA
    J Clin Oncol 23:6647-56. 2005
    ..This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs...
  83. ncbi request reprint Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M Chang
    University of California, San Francisco, San Francisco, CA 94143, USA
    Invest New Drugs 23:357-61. 2005
    ..CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug...
  84. pmc A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study
    H Ian Robins
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Neuro Oncol 4:109-14. 2002
    ..The significant myeloprotection afforded by thymidine may have particular relevance to polychemotherapeutic regimens...
  85. pmc A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    University of California, San Francisco, San Francisco, California 94143 0372, USA
    Neuro Oncol 8:189-93. 2006
    ..52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population...
  86. ncbi request reprint Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  87. ncbi request reprint Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  88. ncbi request reprint Chemotherapy and cerebral metastases: misperception or reality?
    Robert Cavaliere
    Dardinger Neuro oncology Center, The Ohio State University, Columbus, Ohio, USA
    Neurosurg Focus 22:E6. 2007
    ..Acceptable control arms must be established to measure the effect of chemotherapies. Standardized response criteria and disease-specific studies are essential...
  89. ncbi request reprint A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  90. pmc Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
    John G Kuhn
    Pharmacotherapy Education and Research Center, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Clin Cancer Res 13:7401-6. 2007
    ..An additional objective was to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue...
  91. ncbi request reprint Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M Chang
    Neuro Oncology Service, University of California, San Francisco, CA 94143, USA
    Invest New Drugs 22:427-35. 2004
    ..The objectives of this study were to determine the pharmacokinetic profile and the maximum tolerated dose of CCI-779 in patients with recurrent malignant gliioma taking EIAEDs...
  92. pmc Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
    Santosh Kesari
    Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neuro Oncol 9:354-63. 2007
    ..While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted...
  93. pmc O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas
    S Clifford Schold
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Neuro Oncol 6:28-32. 2004
    ..We conclude that a BG dose of 120 mg/m(2) given 6 h before an alkylating drug would be effective in suppressing AGT and possibly potentiating the cytotoxic effects of the drug...
  94. ncbi request reprint Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  95. ncbi request reprint Which donors with brain tumors are safe?
    David Schiff
    Transplantation 77:1906; author reply 1906-7. 2004
  96. pmc CNS Hodgkin lymphoma
    Elizabeth R Gerstner
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Blood 112:1658-61. 2008
    ....
  97. ncbi request reprint Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study
    Deborah J Cook
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
    J Crit Care 20:364-72. 2005
    ..Its additional goals were to evaluate the suitability of the exclusion criteria and to document the range of research activities that precede accrual of patients into a trial to plan multisite management...
  98. ncbi request reprint Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri
    David Schiff
    Neurology 61:425; author reply 425. 2003
  99. ncbi request reprint The risks of immunosuppression
    David Schiff
    Int J Clin Pract 57:744; author reply 744. 2003
  100. ncbi request reprint International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  101. ncbi request reprint Cerebral metastases--a therapeutic update
    Robert Cavaliere
    Dardinger Neuro Oncology Center at The Ohio State University, Columbus, OH, USA
    Nat Clin Pract Neurol 2:426-36. 2006
    ..As the arsenal of therapeutics expands, it will be increasingly important to select appropriate patients for a particular treatment paradigm. Understanding the efficacy and toxicity of treatment is essential to this task...